ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "renal disease and systemic lupus erythematosus (SLE)"

  • Abstract Number: 765 • 2018 ACR/ARHP Annual Meeting

    Predictors of End-Stage Renal Disease in Lupus Nephritis

    Mery Deeb1, Konstantinos Tselios2, Dafna D Gladman2, Jiandong Su2 and Murray Urowitz3, 1Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toront, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: End-stage renal disease (ESRD) is the most important complication of lupus nephritis (LN) and greatly affects mortality. Its incidence has been estimated at 11%…
  • Abstract Number: 722 • 2018 ACR/ARHP Annual Meeting

    Increased Blood Pressure Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus: Association with Inflammation, Comorbidities and Increased Mortality

    Tyler Reese1, Alyson Dickson1, Jacquelyn E. Neal2, Jocelyn S. Gandelman3, Omair A. Khan2, April Barnado4, William Dupont2, C. Michael Stein1 and Cecilia P. Chung1, 1Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 2Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, 3Vanderbilt University School of Medicine, Nashville, TN, 4Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased mortality compared to the general population. As outcomes related to disease control have improved, this mortality…
  • Abstract Number: 735 • 2018 ACR/ARHP Annual Meeting

    Serum Albumin at One Year Predicts Long-Term Renal Outcome

    Vinicius Domingues1, Daniel Goldman2, Laurence S Magder3 and Michelle Petri2, 1Medicine, New York University School of Medicine, New York, NY, 2Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, 3Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose:   Lupus nephritis remains a major cause of morbidity/mortality in SLE.  Our cohort has shown that 20% of SLE patients with lupus nephritis onset…
  • Abstract Number: 739 • 2018 ACR/ARHP Annual Meeting

    Urine and Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Differentially Correlates with Renal and Non-Renal Systemic Lupus Erythematosus (SLE): A Prospective, Case-Control Study

    Yair Molad1,2, Mohammad Egbaria3, Ariela Dortort-Lazar4,5, Elisheva Pokroy-Shapira3,5, Shirly Oren4, Yonatan Edel3,5 and Vitaly Kliminski5,6, 1Rheumatology Unit, Rabin Medical Center - Beilinson Campus, Petah-Tiqva, Israel, 2Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel, 3Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, 4Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel, 5Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 6Laboratory of Inflammation Research, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva, Israel

    Background/Purpose: Elevated levels of sTREM-1 have been previously found in patients with SLE. A prospective, case-control, longitudinal study aimed to assess the value of urinary…
  • Abstract Number: 763 • 2018 ACR/ARHP Annual Meeting

    Comparison of Clinical Characteristics and Outcome between Isolated and Classic Lupus Nephritis

    Kubra Bugdayli1, Cynthia S. Crowson2, Ladan Zand3, Mariam P. Alexander4, Lynn D. Cornell4 and Vaidehi R. Chowdhary5, 1Department of Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, 2Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Nephrology and Hypertension, Mayo Clinic, Rochester, MN, 4Anatomic Pathology, Mayo Clinic College of Medicine and Science, Rochester, MN, 5Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN

    Comparison of clinical characteristics and outcome between isolated and classic lupus nephritisBackground/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE). Rarely,…
  • Abstract Number: 665 • 2017 ACR/ARHP Annual Meeting

    Low Vitamin D Is Associated with End Stage Renal Disease in Systemic Lupus Erythematosus

    Michelle Petri1, Wei Fu2 and Daniel Goldman2, 1Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, 2Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Vitamin D insufficiency/deficiency is common in SLE. Replacement therapy may help renal disease activity. We asked whether low vitamin D predicted later organ damage.…
  • Abstract Number: 2621 • 2017 ACR/ARHP Annual Meeting

    Minimal Renal Affection in Patients with Systemic LUPUS Erythematosus: Characteristics and Evolution

    TC Salman-Monte1, Eva Rodriguez2, José Luis Arevalos3, María José Soler3, Clara Barrios3, Jordi Carbonell4 and Julio Pascual3, 1Rheumatology, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain, 2Nephrology, Hospital del Mar/ Parc de Salut Mar, Barcelona, Spain, 3Nephrology, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain, 4Rheumatology Unit, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain

    Background/Purpose: Lupus nephritis (LN) is the most common organ involvement in Systemic Lupus Erythematosus (SLE). Indications of renal biopsy (RB) are deterioration of renal function…
  • Abstract Number: 2622 • 2017 ACR/ARHP Annual Meeting

    The Benefit of Vitamin D on SLE Disease Activity Is Largely Explained By Renal Activity

    Michelle Petri1, Daniel Goldman2 and Laurence S Magder3, 1Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, 2Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: Low vitamin D is commonly found in SLE. In previous studies, supplementation of vitamin D resulted in improvement in the Physician Global Assessment and…
  • Abstract Number: 1181 • 2016 ACR/ARHP Annual Meeting

    Risk Factors for Incident Fractures in Patients with Systemic Lupus Erythematosus on Dialysis

    Brian Le1,2, Jennifer Waller3, Reshmitha Radhakrishnan4, Sun Jung Oh4, Monique Bethel2,5, Christopher Rice4 and Laura Carbone2,6, 1Department of Internal Medicine, Augusta University, Augusta, GA, 2Specialty Care, Charlie Norwood VA Medical Center, Augusta, GA, 3Biostatistics, Augusta University, Augusta, GA, 4School of Medicine, Augusta University, Augusta, GA, 51120 15th Street, BI 5070, Augusta University, Augusta, GA, 6Rheumatology, Augusta University, Augusta, GA

    Background/Purpose:  Osteoporosis and osteoporotic fractures are significant comorbidities in patients with systemic lupus erythematosus (SLE). Hip fractures are being increasingly recognized as a complication of…
  • Abstract Number: 2827 • 2016 ACR/ARHP Annual Meeting

    Prognostic Significance of Repeat Biopsy in Lupus Nephritis: Histopathologic Worsening Is an Independent Risk Factor for End Stage Renal Disease and Death

    Cristina Arriens1, Sixia Chen2, David Karp3, Ramesh Saxena4, Kamalanathan Sambandam4, Eliza Chakravarty1, Judith A. James5 and Joan T. Merrill6, 1Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Internal Medicine/Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, 4Internal Medicine/Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, 5Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose:  Approximately half of SLE patients develop lupus nephritis (LN), a major cause of morbidity and early mortality. It is known that prolonged renal inflammation…
  • Abstract Number: 2868 • 2016 ACR/ARHP Annual Meeting

    NK Cell Characterization in Patients with Systemic Lupus Erythematosus: Increased Frequency of Ki67+ NK Cells Associated with Disease Activity and Type I Interferon Signature

    Kelly Hudspeth1, Shu Wang2, Jingya Wang2, Saifur Rahman2, Michael Smith2, Kerry Casey2, Geoffrey Stephens3, Miguel Sanjuan2, Autoimmunity Molecular Medicine group2, Zerai G. Manna4, Sarfaraz Hasni4, Rachel Ettinger5 and Richard Siegel6, 1Immunoregulation Section, Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Respiratory, Inflammation, and Autoimmunity Group, MedImmune LLC, Gaithersburg, MD, 3Respiratory, Inflammatory, and Autoimmune Diseases Research, Medimmune, LLC, Gaithersburg, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 5Respiratory, Inflammation and Autoimmunity (RIA), MedImmune, LLC, Gaithersburg, MD, 6Immunoregulation Section, Autoimmunity Branch and Office of the Clinical Director National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disorder whose pathology appears to involve many immune cell types. While it is clear that autoantibody…
  • Abstract Number: 1658 • 2014 ACR/ARHP Annual Meeting

    Renal Thrombotic Microangiopathy in Systemic Lupus Erythematosus: Novel Risk Factors and Clinical Outcomes

    Ana Barrera-Vargas1, Rodrigo Rosado-Canto2, Javier Merayo-Chalico3, Jorge Alcocer-Varela1 and Diana Gómez-Martín1, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, 3Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Background/Purpose: Thrombotic microangiopathy (TMA) is characterized by microvascular occlusion, systemic or intrarenal platelet aggregation and mechanical injury to erythrocytes.  It is a pathological endpoint that…
  • Abstract Number: 618 • 2013 ACR/ARHP Annual Meeting

    Active Renal Disease Is Associated With The Presence Of The Metabolic Syndrome (MetS) In Peruvian Patients With Systemic Lupus Erythematosus (SLE)

    Manuel F. Ugarte-Gil1,2, Rocio V. Gamboa-Cardenas3, Mariela Medina-Chinchon1, Francisco Zevallos-Miranda1, Karim E. Diaz-Deza3, J. Mariano Cucho-Venegas1, Zoila Rodriguez-Bellido1,4, Jose L. Alfaro-Lozano1, Risto A. Perich-Campos1,4, Erika Noriega3, Hugo Torrealva1 and Cesar A. Pastor-Asurza1,4, 1Rheumatology, Hospital Guillermo Almenara, EsSalud, Lima, Peru, 2Universidad Cientifica del Sur, Lima, Peru, 3Rheumatology, Hospital Almenara, Lima, Peru, 4Universidad Nacional Mayor de San Marcos, Lima, Peru

    Background/Purpose: The MetS prevalence is increased in SLE patients, in particular in those of Hispanic origin and it is associated with a higher risk for…
  • Abstract Number: 594 • 2013 ACR/ARHP Annual Meeting

    Renal Biopsy Findings In Lupus Patient With Insignificant Proteinuria : Relation To Disease Activity and Clinical Manifestations

    Abdel Azeim M. Al-Hefny1, Samah El-bakry2, Sameh A. Mobasher3, Ola H. Nada4 and Nouran Abaza5, 1Department of Internal Medicine and Rheumatology, Professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, Cairo, Egypt, 2Department of Internal Medicine and Rheumatology, Assistant professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, 3Department of Internal Medicine and Rheumatology, Lecturer of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, 4Department of Pathology, Faculty of Medicine, Ain Shams University, Lecturer of Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, 5Physical medicine, Rheumatology and Rehabilitation, Lecturer of Physical medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    Background/Purpose: Lupus nephritis (LN) remains one of the most serious manifestations of systemic lupus erythematosus (SLE) and is associated with significant morbidity and mortality. Early…
  • Abstract Number: 2265 • 2012 ACR/ARHP Annual Meeting

    Clinical Manifestations of Systemic Lupus Erythematosus Vary Based On Age of Disease Onset

    Flora Simmons1, Natasha M. Ruth2, Gary S. Gilkeson3 and Diane L. Kamen4, 1Rheumatology, Medical University of South Carolina, Charleston, SC, 2Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, 3Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 4Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC

    Background/Purpose:  Systemic lupus erythematosus (SLE) is an autoimmune disease which disproportionately affects women of child-bearing age.  However, onset during childhood and late adult onset can…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology